ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to overcoming resistance in cancer. The company focuses on three biological areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Leveraging the deep expertise of its founders and management team, ORIC Pharmaceuticals advances a pipeline of product candidates designed to counteract mechanisms such as PRC2 dysregulation and EGFR exon 20 mutations. Its lead programs include rinzimetostat, an allosteric inhibitor of the PRC2 complex via the EED subunit, and enozertinib, a brain‑penetrant irreversible inhibitor targeting EGFR exon 20 and atypical mutations. The firm conducts research and development primarily from facilities in South San Francisco and San Diego, California, and employs 104 full‑time staff as of December 31, 2025.
ORIC Pharmaceuticals generates revenue mainly through upfront payments, milestone payments, and potential royalties from its licensing and collaboration agreements. Under the Voronoi License Agreement, the company received an upfront cash payment of $5.0 million and issued 283,259 shares valued at $28.24 per share. Under the Mirati License Agreement, ORIC Pharmaceuticals issued 588,235 shares valued at $34.00 per share as an upfront payment and is eligible to receive up to $111.0 million in development milestones and up to $225.0 million in commercial milestones from Voronoi, plus additional success‑based payments for a second licensed product. The company also has clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer, which provide funding for ongoing studies of rinzimetostat in combination with apalutamide and darolutamide. ORIC Pharmaceuticals has not yet commercialized any therapeutic and therefore does not record product sales revenue.
ORIC Pharmaceuticals competes in the oncology sector by addressing resistance mechanisms that limit the durability of existing therapies. For rinzimetostat, the company faces competition from firms developing EZH2 inhibitors such as Ipsen, Novartis, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical, Treeline Biosciences in collaboration with Jiangsu HengRui Medicine, Evopoint Biosciences, and Hanmi Pharmaceutical, as well as Ascentage Pharma, which is advancing an allosteric PRC2 inhibitor. In the enozertinib program, ORIC Pharmaceuticals competes with Johnson & Johnson and Dizal Pharmaceuticals, which hold FDA‑approved therapies for EGFR exon 20 mutations, and with numerous other companies developing small‑molecule EGFR exon 20 inhibitors including Cullinan Therapeutics with Taiho Pharmaceutical, ArriVent BioPharma with Allist Pharmaceuticals, Black Diamond Therapeutics, Scorpion Therapeutics with Pierre Fabre, BlossomHill Therapeutics, Avistone Biotechnology, BeBetter Med, Suzhou Puhe Pharmaceutical Technology, and Yuhan Corporation. The company’s competitive advantages derive from its founders’ proven track record in discovering and commercializing cancer medicines such as Rozlytrek, Erleada, Talzenna, Xtandi, Sprycel, Gleevec, Imbruvica, and Zelboraf, its expertise in biomarker‑driven patient selection, and the differentiated pharmacology of its candidates, notably enozertinib’s high brain‑to‑plasma ratio and rinzimetostat’s allosteric EED binding that may overcome resistance seen with EZH2‑targeted agents.
ORIC Pharmaceuticals serves patients with cancer who participate in its clinical trials, and collaborates with pharmaceutical partners such as Johnson & Johnson and Bayer to evaluate combination regimens of its product candidates. The company works with clinical trial sites, investigators, and healthcare providers to enroll patients and collect safety and efficacy data. While ORIC Pharmaceuticals intends to eventually market its therapies directly to patients, hospitals, and healthcare systems, its current customer base consists primarily of these collaboration partners, trial participants, and the medical centers that host its studies.